376 related articles for article (PubMed ID: 3917475)
1. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
Itoh K; Tilden AB; Kumagai K; Balch CM
J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
[TBL] [Abstract][Full Text] [Related]
2. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interleukin 2 enhanced natural killer cell-mediated cytotoxicity in human lymphocyte subpopulations expressing the Leu 7 and Leu 11 antigens.
Lanier LL; Benike CJ; Phillips JH; Engleman EG
J Immunol; 1985 Feb; 134(2):794-801. PubMed ID: 3871216
[TBL] [Abstract][Full Text] [Related]
4. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
Tilden AB; Itoh K; Balch CM
J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
Ferrini S; Miescher S; Zocchi MR; von Fliedner V; Moretta A
J Immunol; 1987 Feb; 138(4):1297-302. PubMed ID: 3100633
[TBL] [Abstract][Full Text] [Related]
6. Mode of in vitro augmentation of natural killer cell activity by recombinant human interleukin 2: a comparative study of Leu-11+ and Leu-11- cell populations in cord blood and adult peripheral blood.
Seki H; Ueno Y; Taga K; Matsuda A; Miyawaki T; Taniguchi N
J Immunol; 1985 Oct; 135(4):2351-6. PubMed ID: 3928745
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2- and mitogen-activated NK-like killer cells from highly purified human peripheral blood T cell (CD3+ N901-) cultures.
Atzpodien J; Wisniewski D; Gulati S; Welte K; Knowles R; Clarkson B
Nat Immun Cell Growth Regul; 1987; 6(3):129-40. PubMed ID: 3114621
[TBL] [Abstract][Full Text] [Related]
8. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
10. Prerequisite for the induction of lymphokine-activated killer cells from T lymphocytes.
Sawada H; Abo T; Sugawara S; Kumagai K
J Immunol; 1988 May; 140(10):3668-73. PubMed ID: 2896211
[TBL] [Abstract][Full Text] [Related]
11. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
Burns GF; Triglia T; Werkmeister JA
J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
[TBL] [Abstract][Full Text] [Related]
12. Bacterial activation of human natural killer cells. Characteristics of the activation process and identification of the effector cell.
Tarkkanen J; Saksela E; Lanier LL
J Immunol; 1986 Oct; 137(8):2428-33. PubMed ID: 3093576
[TBL] [Abstract][Full Text] [Related]
13. Large granular lymphocytes are central cells in the interleukin-2-dependent differentiation pathway of natural killer cells.
Lange A; Ernst M; Jaźwiec B; Ennen J; Flad HD
Nat Immun Cell Growth Regul; 1987; 6(5):237-49. PubMed ID: 3502170
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
16. Precursor phenotype of lymphokine-activated killer cells in the mouse.
Salup RR; Mathieson BJ; Wiltrout RH
J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
[TBL] [Abstract][Full Text] [Related]
17. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
[TBL] [Abstract][Full Text] [Related]
18. In vivo antitumor activity of anti-CD3-induced activated killer cells.
Yun YS; Hargrove ME; Ting CC
Cancer Res; 1989 Sep; 49(17):4770-4. PubMed ID: 2527087
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.
Damle NK; Doyle LV; Bradley EC
J Immunol; 1986 Nov; 137(9):2814-22. PubMed ID: 2944965
[TBL] [Abstract][Full Text] [Related]
20. Killer cell recruitment and renewal capacity of purified cytolytic and noncytolytic human peripheral blood natural killer cell subsets.
Lebow LT; Jewett A; Bonavida B
J Immunol; 1993 Jan; 150(1):320-9. PubMed ID: 8417130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]